Metro Drug

What Metro Drug does

Metro Drug Inc. (MDI) is a Philippine pharmaceutical and healthcare product distributor founded in its current legal form in 1997, headquartered in Sta. Rosa, Laguna, with operational roots tracing back to Metro Drug Corporation established in 1931. The company distributes pharmaceutical and over-the-counter (OTC) products, medical devices and diagnostics, and animal health products on behalf of more than 50 principal partners — a mix of multinational, local, and pan-Asian manufacturers — covering most therapeutic classes. Distribution reaches all channels of access in the Philippines, including remote areas, via direct pharmacy, hospital, veterinary, livestock, farm, institutional, retail, and e-commerce routes. MDI complements its distribution core with the MeDassIst patient solution program (launched 2019), MDI Commercial Solutions (launched 2018), and a partnership with Interpharma Solutions Inc. (ISPI), the healthcare solutions arm of Zuellig Pharma, for total supply chain, patient, vaccination, and digital health services.

The company's underlying operating technology is conventional for the sector: an online inventory monitoring system for stock visibility across the network, cold chain compliant infrastructure for temperature-sensitive animal health products, and a nationwide warehousing and logistics backbone. These are integration- and safety-oriented capabilities rather than differentiated AI/data systems. The revenue model is transaction-fee-based distribution: MDI earns margins and distribution fees on products moved through its network on behalf of its principals. The company employs 501-1,000 people, positions itself among the top 100 corporations in the Philippines, and reports strong top-line growth over the past five years driven by focused management, streamlined operations, and new principal acquisition. Underlying this growth is a competency in working capital management, which is cited as a key factor in MDI's credibility with principals and customers. The company remains privately held, with no disclosed institutional investors or public listing.

Name

Metro Drug

Legal name

Metro Drug Inc.

Website

https://metrodruginc.com.ph

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Metro Drug Inc. is a Philippine pharmaceutical, medical device, and animal health distributor serving 50+ multinational and local principals across all channels nationwide, including remote areas, with complementary patient solutions and commercial services.

Ownership category

akta.pro rank

Product category

Pharmaceutical Distribution

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Pharmaceutical & Healthcare Distribution Centers (GDP-compliant) (TLALAEAE)

Keywords

• Pharmaceutical distribution
• Healthcare logistics
• Medical device distribution
• Animal health distribution
• Cold chain distribution

Headquarters

HQ city

Laguna

HQ country

Philippines

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Infrastructure, Supply Chain, Personnel, Technology or R&D

Revenue model

1. Pharmaceutical and Healthcare Distribution: Metro Drug Inc. earns revenue as a pharmaceutical and healthcare product distributor, providing distribution services to principal partners (multinational, local, and pan-Asian pharma and healthcare companies) across all channels of access in the Philippines. Revenue is generated through distribution fees and margins on the products distributed through its network.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels2 records

Core offering

Metro Drug Inc. is a Philippine pharmaceutical and healthcare distribution company that provides route-to-market services for multinational, local, and pan-Asian pharmaceutical, over-the-counter (OTC), medical device, diagnostic, and animal health companies. It operates a nationwide distribution network reaching all channels of access including the most remote areas, leveraging warehousing, logistics, cold chain compliant infrastructure, and online inventory monitoring.

Product overview

Metro Drug Inc. operates as a pharmaceutical and healthcare distribution company offering four distinct product/service lines: Pharma/OTC Distribution (core pharmaceutical and over-the-counter product distribution), Medical Devices Distribution (solutions for medical device manufacturers and diagnostic companies), MDI Animal Health (cold chain-compliant animal health product distribution), and ISPI Partnership (total supply chain and patient solutions through Zuellig Pharma). The company also provides MedAssist and MDI Commercial Solutions as supporting services, along with the MeDassIst Patient Solution Program launched in 2019.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharma/OTC Distribution
• Medical Devices Distribution
• MDI Animal Health
• MDI Commercial Solutions

Quantifiable outcome

• Reached over 50 principal partners across multinational, local, and pan-Asian companies, covering most therapeutic classes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Marsman & Co., Inc.coreStrategic or Co-development Partner · 1 January 1995MDDI was acquired and strategically merged with Marsman & Company, Inc. in 1995. In 1997, Marsman incorporated Metro Drug Inc. to handle the pharmaceutical distribution business of former MDDI. Marsman was an affiliate of the Zuellig Group of Companies. Senior management structure was changed in 1999 to the lean, flat organization operating today.
• First Pacific Company Ltd of Hong KongminorStrategic or Co-development Partner · 1 January 1987In 1987, First Pacific Company Ltd of Hong Kong acquired Metro Drug Corporation and it became known as Metro Drug Distribution Inc. This was a historical corporate acquisition that preceded the current structure of Metro Drug Inc.
• Interpharma Solutions Inc. (ISPI)coreStrategic or Co-development PartnerMetro Drug Inc. partners with Interpharma Solutions Inc. (ISPI), the Healthcare Solutions company of Zuellig Pharma. ISPI focuses on providing total supply chain solutions, patient solutions, vaccinations, and digital health platforms. This partnership extends MDI's capabilities beyond traditional distribution into comprehensive healthcare solutions.
• Zuellig Group of CompaniescoreStrategic or Co-development PartnerHistorical relationship: In 1995, MDDI was acquired and strategically merged with Marsman & Company, Inc., an affiliate of the Zuellig Group of Companies. In 1997, Metro Drug Inc. was incorporated by Marsman to handle the pharmaceutical distribution business of former MDDI. The Zuellig connection remains relevant through the ISPI partnership.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Regional players

• Alfresa Holdings: Alfresa is another of Japan's leading pharmaceutical wholesalers with diversified healthcare distribution including animal health. Comparable to MDI in business model breadth — pharma, medical devices, and animal health under one national distribution platform.
• Medipal Holdings: Medipal is one of Japan's four major pharmaceutical wholesalers, operating a similar pharma and healthcare distribution model at scale. While Japan-only, it is structurally analogous to MDI: principal-partner relationships, nationwide logistics, and adjacent consumer health / animal health exposure.
• Suzuken: Suzuken is a major Japanese pharma wholesaler operating a national distribution network serving hospitals, clinics, and pharmacies. Comparable to MDI in the principal-to-customer pharmaceutical distribution model and in coverage of most therapeutic categories.

Direct peers

• DKSH Holding: DKSH is a Swiss-listed market expansion services company with a major Healthcare distribution business across Asia. It runs a similar principal-partner distribution model for pharmaceuticals, medical devices, and consumer health products, making it a close functional and strategic comparable to MDI's four commercial pillars.
• Phoenix Group: Phoenix Group is the leading pharmaceutical distributor in Europe, operating across 29 countries with comparable principal-partner pharma distribution, medical devices, and patient solutions services. Closest European functional comparable to MDI's full-service distribution plus adjacent healthcare solutions offering.
• Zuellig Pharma: Zuellig Pharma is the largest pharmaceutical distributor in Asia and the most direct comparable to Metro Drug — same pharma distribution model, same region, and a historic relationship through the Zuellig Group of Companies that previously owned MDDI/MDI. Both companies operate national pharma distribution networks serving multinational and local principals across Southeast Asia.

Broad incumbents

• Henry Schein: Henry Schein is a leading global distributor of medical and dental supplies, including practice management and diagnostic solutions. Comparable to MDI's medical devices and diagnostics commercial pillar, which differentiates MDI from pure pharma distributors and positions it against medical-device specialists.
• Cencora: Cencora (formerly AmerisourceBergen) is one of the largest global pharmaceutical distributors with broad healthcare services. While US-anchored and far larger, it represents the incumbent-scale version of MDI's principal-partner pharma distribution business and a benchmark for the trajectory of large pharma wholesalers.
• McKesson: McKesson is a top-tier global pharmaceutical and medical device distributor with extensive distribution, biopharma services, and pharmacy solutions. Comparable as the broad incumbent whose operating model (and threat profile for Asian principals) MDI's lean structure is positioned against.
• Cardinal Health: Cardinal Health operates large-scale pharmaceutical and medical product distribution in the US and globally. Comparable to MDI's combined pharmaceutical and medical device distribution footprint, with a much broader portfolio that highlights the convergence direction MDI is pursuing through its medical device division.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Metro Drug